| Literature DB >> 24606609 |
Weiwu Jin, Eveline M Ibeagha-Awemu, Guanxiang Liang, Frédéric Beaudoin, Xin Zhao1, Le Luo Guan.
Abstract
BACKGROUND: MicroRNAs (miRNAs) can post-transcriptionally regulate gene expression and have been shown to be critical regulators to the fine-tuning of epithelial immune responses. However, the role of miRNAs in bovine responses to E. coli and S. aureus, two mastitis causing pathogens, is not well understood.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24606609 PMCID: PMC4029070 DOI: 10.1186/1471-2164-15-181
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Detected small RNAs. A pie graph showing the relative abundance of different classes of small RNAs (A); size distribution of small RNAs or miRNAs (B); frequency distribution of each size (18–30 nts) of small RNAs or all known miRNAs based on all reads (C). miRNA here only indicates known bovine miRNAs in miRBase (Release 19).
Top expressed miRNAs in bovine MAC-T cells with or without challenge with or bacteria
| bta-miR-21-5p | 1494737 | 16.02% | 15.89% | 16.18% | 16.07% |
| bta-miR-27b | 1416234 | 15.18% | 14.65% | 15.46% | 15.77% |
| bta-miR-22-3p | 780733 | 8.37% | 8.61% | 8.38% | 7.95% |
| bta-miR-184 | 508224 | 5.45% | 5.65% | 5.27% | 5.30% |
| bta-let-7f | 467126 | 5.01% | 4.83% | 4.94% | 5.39% |
| bta-miR-205 | 424274 | 4.55% | 4.56% | 4.67% | 4.39% |
| bta-miR-92a | 363202 | 3.89% | 3.74% | 4.02% | 4.01% |
| bta-miR-182 | 362632 | 3.89% | 3.60% | 3.87% | 4.41% |
| bta-miR-31 | 261303 | 2.80% | 2.92% | 2.80% | 2.60% |
| bta-let-7a-5p | 190668 | 2.04% | 2.19% | 1.81% | 2.05% |
| bta-miR-222 | 172392 | 1.85% | 1.88% | 1.84% | 1.80% |
| bta-let-7i | 166440 | 1.78% | 1.73% | 1.75% | 1.92% |
| bta-miR-221 | 141821 | 1.52% | 1.57% | 1.51% | 1.44% |
| bta-miR-26a | 129420 | 1.39% | 1.45% | 1.39% | 1.28% |
| bta-miR-148a | 123204 | 1.32% | 1.24% | 1.40% | 1.37% |
| bta-miR-27a-3p | 118012 | 1.26% | 1.34% | 1.26% | 1.14% |
| bta-miR-186 | 104935 | 1.12% | 1.12% | 1.15% | 1.10% |
| bta-miR-191 | 103301 | 1.11% | 1.08% | 1.13% | 1.12% |
| Total | 7328656 | 78.55% | 78.04% | 78.84% | 79.11% |
*Ratio refers to the total number of reads of a miRNA as compared to all reads of known bovine miRNAs detected in this study (miRBase Release 19).
A partial list of novel miRNAs identified in bovine MAC-T cells with or without challenge with bacteria
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| eca-mir-1842 | eca-miR-1842 | 1180.4 | 2,172 | uggcucugugaggucggcuca | 21 | 142 | agcaggccugucagggcguug | 21 | 25:1744660..1744720:- | |
| ssc-mir-219 | ssc-miR-219 | 68.9 | 103 | agaguugagucuggacgucccg | 22 | 20 | ugauuguccaaacgcaauuc | 20 | 23:7335349..7335412:- | |
| ssc-mir-664 | ssc-miR-664-3p | 68.5 | 70 | uauucauuuaucucccagccuaca | 24 | 59 | caggcuaggagaaaugauuggau | 23 | 16:24379875..24379936:- | |
| gga-mir-6516 | | 9.6 | 10 | uuugcaguaacaggugugaac | 21 | 9 | aucauguaugauacugcaaaca | 22 | 19:55419754..55419817:+ | |
| bta-mir-219-1′ | hsa-miR-2964a-3p | 20.7 | 27 | agaauugcguuuggacaaucagu | 23 | 5 | gauguccagccacaauucucg | 21 | 11:98997166..98997230:+ | |
| bta-mir-200a′ | rno-miR-3548 | 6.6 | 2 | cagcacuguccgguaagauguc | 22 | 2 | caucguuaccagacaguguuaga | 23 | 16:52521338..52521399:+ | |
| bta-mir-194-1′ | | 30.4 | 56 | acauggaguugcuguuacaaucg | 23 | 3 | aaguaacagcaucuccacugga | 22 | 16:24306044..24306105:+ | |
| bta-mir-486′ | | 27.8 | 48 | cccgguacugagcugacccgag | 22 | 4 | ucggggcagcucaguacaggac | 22 | 27:36261849..36261912:+ | |
| bta-mir-374a′ | bta-miR-374a-3p | 26.1 | 50 | uuacaauacaaccugauaagug | 22 | 1 | acuuaucagguuguauuaua | 20 | X:81951234..81951283:- | |
| bta-mir-763′ | | 6.8 | 8 | ucccagcuggucauuaauccu | 21 | 3 | gaauuaauggcuggcugggagg | 22 | 5:48164035..48164101:+ | |
| bta-mir-191′ | bta-miR-191 | 5.5 | 40 | gaacgaaauccaagcgcagcug | 22 | 0 | gcugcuuuugggauuccguugcc | 23 | 22:51543481..51543545:- | |
| bta-mir-1388′ | bta-miR-1388-5p | 1.8 | 405 | uucucagguuggacaguccuga | 22 | 0 | cgggcugacaaaccugagauug | 22 | 13:54375941..54376002:- | |
| bta-mir-374b′ | bta-miR-374-3p | 1.4 | 60 | ugauaauacaaccugauaagug | 22 | 0 | cuuagcagguuguauuauaucc | 22 | X:82023929..82023981:- | |
| bta-mir-194-2′ | bta-miR-194 | 4.8 | 10 | cacauggaguugcuguuaca | 20 | 0 | uaacagcagccccacugga | 19 | 29:43731473..43731526:- | |
| eca-mir-590 | | 1.4 | 13 | uaguuuuauguguaagcucguu | 22 | 0 | cgagcuuauucacagaaguaca | 22 | 25:33713356..33713419:- | |
| bta-miR-222 | 4.9 | 20 | ugcuacaucuggcuacugga | 20 | 0 | ggguggacgcuguguggcugagc | 23 | 10:78769129..78769183:+ |
1“`”represents the antisense of miRNA precursor; the star sequence of miR-219-2 is miR-219-5p in miRBase (Release 19);
2The top known miRNA precursor (miRBase Release 19) aligns to novel precursor with > 70 identity and > 75 sequence length;
3The top known miRNA (miRBase Release 19) matches novel miRNA covering > 90 identity and > 90 sequence length;
4Sequence here only shows the dominant one and the star sequence that was absent was predicted by miRDeep2.
5miRNA with score less than 5 is identified from miRNA candidate precursor.
Figure 2Five differentially expressed miRNAs in control cells over time as compared to 0 hr.
Significantly differentially expressed miRNAs in MAC-T cells between treatments (challenged with or bacteria) and controls at same time points
| | | | | | | |||
|---|---|---|---|---|---|---|---|---|
| 6 h | bta-miR-193a-3p | 0.37 | -1.416 | 4.30E-06 | bta-miR-2339 | 4.56 | 2.188 | 0.0427 |
| | bta-miR-365-3p | 1.52 | 0.608 | 4.47E-03 | | | | |
| | bta-miR-184 | 1.27 | 0.343 | 0.019 | | | | |
| | bta-miR-24-3p | 1.33 | 0.411 | 0.0229 | | | | |
| | bta-miR-30c | 0.75 | -0.406 | 0.024 | | | | |
| | bta-miR-30b-5p | 0.71 | -0.502 | 0.048 | | | | |
| 12 h | bta-miR-21-3p | 1.85 | 0.886 | 1.27E-03 | bta-miR-21-3p | 1.79 | 0.836 | 4.20E-03 |
| | bta-miR-148a | 1.43 | 0.516 | 0.0200 | bta-miR-423-5p | 0.67 | -0.578 | 0.0168 |
| | bta-miR-423-5p | 0.69 | -0.545 | 0.0205 | bta-miR-499 | 0.06 | -3.998 | 0.0300 |
| | bta-miR-92a | 1.37 | 0.454 | 0.0389 | bta-miR-92a | 1.36 | 0.449 | 0.0428 |
| 24 h | bta-miR-423-5p | 1.58 | 0.658 | 1.21E-03 | bta-miR-193a-3p | 0.62 | -0.700 | 7.78E-03 |
| | bta-miR-21-3p | 1.68 | 0.751 | 2.43E-03 | bta-miR-23a | 1.46 | 0.550 | 0.0137 |
| | bta-let-7a-5p | 0.69 | -0.544 | 3.43E-03 | bta-miR-99b | 0.69 | -0.540 | 0.0154 |
| | bta-miR-184 | 0.76 | -0.394 | 0.0326 | bta-miR-21-3p | 1.55 | 0.636 | 0.0191 |
| | bta-miR-un5 | 0.52 | -0.940 | 0.0444 | bta-miR-un5 | 0.47 | -1.077 | 0.0238 |
| 48 h | bta-miR-486 | 1.94 | 0.955 | 6.46E-04 | bta-miR-193a-3p | 0.20 | -2.302 | 4.49E-08 |
| | bta-miR-193a-3p | 0.64 | -0.650 | 0.0183 | bta-miR-365-3p | 2.49 | 1.315 | 6.87E-04 |
| | | | | | bta-miR-30c | 0.55 | -0.871 | 0.0191 |
| bta-miR-30b-5p | 0.53 | -0.904 | 0.0241 |
*Fold change values are as compared to controls at same time points.
Results of qPCR validation of the expression of five miRNAs in MAC-T cells between treatments (challenged with or bacteria) and controls at same time points
| | | | |||||
|---|---|---|---|---|---|---|---|
| 6h | bta-miR-193a-3p | 0.342 | 0.039 | 0.630 | 0.054 | ||
| | bta-miR-21-3p | 1.161 | 0.206 | 0.508 | 3.478 | 0.365 | |
| | bta-miR-365-3p | 1.607 | 0.037 | 0.612 | 0.040 | ||
| | bta-miR-423-5p | 1.682 | 0.218 | 2.018 | 0.096 | ||
| | bta-miR-486 | 2.109 | 0.304 | 1.616 | 0.046 | ||
| 12h | bta-miR-193a-3p | 0.992 | 0.023 | 0.911 | 0.601 | 0.085 | 0 |
| | bta-miR-21-3p | 2.154 | 0.276 | 1.062 | 0.272 | 0.819 | |
| | bta-miR-365-3p | 0.930 | 0.115 | 0.568 | 0.994 | 0.106 | 0.962 |
| | bta-miR-423-5p | 0.629 | 0.046 | 0.812 | 0.106 | 0.111 | |
| | bta-miR-486 | 1.614 | 0.168 | 1.630 | 0.342 | 0.142 | |
| 24h | bta-miR-193a-3p | 1.206 | 0.052 | 0.017 | 1.327 | 0.171 | 0.140 |
| | bta-miR-21-3p | 1.942 | 0.410 | 0.092 | 1.222 | 0.066 | |
| | bta-miR-365-3p | 1.051 | 0.358 | 0.879 | 0.890 | 0.096 | 0.478 |
| | bta-miR-423-5p | 1.838 | 0.252 | 1.304 | 0.297 | 0.336 | |
| | bta-miR-486 | 1.099 | 0.030 | 0.545 | 0.867 | 0.119 | 0.480 |
| 48h | bta-miR-193a-3p | 0.353 | 0.053 | 0.336 | 0.026 | ||
| | bta-miR-21-3p | 1.083 | 0.192 | 0.679 | 1.105 | 0.080 | 0.385 |
| | bta-miR-365-3p | 1.612 | 0.067 | 2.809 | 0.204 | ||
| | bta-miR-423-5p | 1.092 | 0.017 | 0.130 | 2.894 | 0.258 | |
| bta-miR-486 | 0.940 | 0.310 | 0.835 | 2.189 | 0.415 | 0.071 | |
*Fold change values are as compared to controls at same time points.
#Bolded numbers indicate the significance with P < 0.05.
Significantly enriched GO (gene ontology) functional annotation of predicted target genes of differentially expressed miRNAs during challenge of MAC-T cells
| Biological adhesion | Bta-miR-23a | 58 | 0.038 (0.11) | - | - | - |
| Biological regulation | Bta-miR193a-3p | 159 | 0.002 (0.039) | Bta-miR-24-3p | 287 | 0.010 (0.070) |
| | Bta-miR365-3p | 142 | 5.5E-5 (3.9E-4) | Bta-miR-148a | 356 | 1.7E-8 (1.3E-7) |
| | Bta-miR-30b-5p/30c | 642 | 4.4E-6 (3.2E-5) | Bta-miR-23a | 565 | 4.0E-9 (4.2E-8) |
| | Bta-miR-499 | 135 | 0.045 (0.11) | Bta-miR-92a | 441 | 7.2E-10 (1.6E-8) |
| | Bta-miR-99b | 31 | 0.007 (0.060) | - | - | - |
| Cellular component organization | Bta-miR-30b-5p/30c | 235 | 2.4E-4 (0.001) | Bta-miR-2339 | 46 | 0.002 (0.016) |
| Bta-let-7a-5p | 182 | 0.040 (0.120) | Bta-miR-23a | 192 | 0.004 (0.016) | |
| | Bta-miR-499 | 60 | 0.001(0.008) | Bta-miR-92a | 144 | 0.016 (0.049) |
| | Bta-miR-148a | 127 | 9.4E-4 (0.005) | Bta-miR-184 | 22 | 0.006 (0.080) |
| Cellular process | Bta-miR193a-3p | 207 | 0.009 (0.096) | Bta-miR-24-3p | 411 | 1.1E-6 (2.3E-5) |
| | Bta-miR423-5p | 337 | 0.034 (0.160) | Bta-miR-148a | 468 | 2.1E-9 (4.7E-8) |
| | Bta-miR365-3p | 180 | 5.7E-4 (0.003) | Bta-miR-2339 | 143 | 0.002 (0.020) |
| | Bta-miR-30b-5p/30c | 889 | 1.1E-10 (2.5E-9) | Bta-miR-23a | 766 | 1.1E-13 (2.4E-12) |
| | Bta-let-7a-5p | 732 | 1.3E-5 (2.5E-4) | Bta-miR-486-5p | 140 | 0.007 (0.067) |
| | Bta-miR-499 | 198 | 8.2E-6 (1.6E-4) | Bta-miR-92a | 567 | 2.0E-7 (1.4E-6) |
| | Bta-miR-99b | 37 | 0.036 (0.100) | - | - | - |
| Death | Bta-miR193a-3p | 21 | 0.038 (0.190) | Bta-miR-24-3p | 35 | 0.046 (0.220) |
| | Bta-miR-30b-5p/30c | 70 | 0.031 (0.083) | Bta-miR-21-3p | 7 | 0.044 (0.930) |
| | Bta-let-7a-5p | 61 | 0.026 (0.087) | Bta-miR-92a | 47 | 0.037 (0.084) |
| | Bta-miR-499 | 21 | 0.014 (0.045) | - | - | - |
| Developmental process | Bta-miR193a-3p | 71 | 0.028 (0.190) | Bta-miR-24-3p | 151 | 1.0E-5 (1.0E-4) |
| Bta-miR423-5p | 114 | 0.024 (0.150) | Bta-miR-148a | 182 | 3.7E-9 (4.1E-8) | |
| | Bta-miR365-3p | 80 | 5.8E-7 (1.3E-5) | Bta-miR-2339 | 57 | 7.1E-4 (0.015) |
| | Bta-miR-30b-5p/30c | 312 | 9.1E-8 (1.0E-6) | Bta-miR-23a | 272 | 2.2E-8 (1.5E-7) |
| | Bta-let-7a-5p | 241 | 0.001 (0.008) | Bta-miR-486-5p | 56 | 0.001 (0.022) |
| | Bta-miR-499 | 74 | 4.1E-4 (0.004) | Bta-miR-92a | 212 | 7.8E-8 (8.5E-7) |
| | Bta-miR-99b | 19 | 0.002 (0.030) | - | - | - |
| Establishment of localization | Bta-miR423-5p | 110 | 3.4E-4 (0.007) | Bta-let-7a-5p | 205 | 0.004 (0.011) |
| Bta-miR-30b-5p/30c | 243 | 9.9E-4 (0.004) | Bta-miR-92a | 159 | 0.003 (0.009) | |
| Growth | Bta-miR-99b | 4 | 0.016 (0.088) | Bta-miR-23a | 20 | 0.026 (0.088) |
| Localization | Bta-miR423-5p | 119 | 8.8E-4 (0.009) | Bta-miR-148a | 147 | 0.001 (0.005) |
| | Bta-miR-30b-5p/30c | 280 | 7.0E-5 (3.9E-4) | Bta-miR-2339 | 49 | 0.015 (0.078) |
| | Bta-let-7a-5p | 233 | 7.2E-4 (0.008) | Bta-miR-92a | 182 | 4.8E-4 (0.002) |
| | Bta-miR-499 | 68 | 0.002 (0.008) | - | - | - |
| Locomotion | Bta-miR193a-3p | 14 | 0.049 (0.200) | Bta-miR-92a | 31 | 0.030 (0.080) |
| | Bta-miR-499 | 17 | 0.002 (0.009) | - | - | - |
| Metabolic process | Bta-miR365-3p | 139 | 9.6E-4 (0.004) | Bta-miR-148a | 334 | 0.001 (0.006) |
| | Bta-let-7a-5p | 538 | 0.001 (0.008) | Bta-miR-23a | 559 | 1.8E-6 (9.7E-6) |
| | Bta-miR-99b | 30 | 0.025 (0.081) | Bta-miR-92a | 395 | 0.039 (0.084) |
| Multicellular organismal process | Bta-miR365-3p | 94 | 2.3E-5 (2.4E-4) | Bta-miR-24-3p | 167 | 0.050 (0.190) |
| Bta-miR-30b-5p/30c | 372 | 0.001 (0.004) | Bta-miR-148a | 196 | 0.005 (0.015) | |
| | Bta-miR-499 | 84 | 0.027 (0.077) | Bta-miR-92a | 258 | 2.2E-5 (1.2-E4) |
| Bta-miR-99b | 20 | 0.023 (0.095) | - | - | - |
*P-Value: The significance of gene-term enrichment with a modified Fisher’s Exact Test.
**Benjamini P-Value: Globally corrects enrichment p-values in order to control family-wide false discovery rate.
KEGG (Kyoto encyclopedia of genes and genomes) pathways significantly enriched by target genes of 14 out of 17* differentially expressed miRNAs during or challenge of MAC-T cells
| | | | | | | | | | | | | | |
| B cell receptor signaling pathway | X | X | | | | | | | | | | | |
| T-cell receptor signaling | | X | X | | | | | | | | | | |
| Fc gamma R-mediated, phagocytosis/chemokine signaling | X | | | X | | | | | | | | | |
| | | | | | | | | | | | | | |
| MAPK signaling pathway | X | X | | X | | X | X | X | X | | | | |
| ErbB signaling pathway | | X | X | | X | X | | | | | | | |
| Wnt signaling pathway | X | X | | X | X | X | | X | | | | | |
| TGF-beta signaling pathway | | | X | X | X | X | | | | | | | |
| Calcium signaling pathway | | | | | | X | X | | X | | | | |
| Phosphatidylinositol pathway | | | | X | | | X | | | | | | |
| ECM-receptor interaction | | | X | | X | | | | | | | | |
| | | | | | |||||||||
| Endocytosis | | X | | X | | X | | | | | | | |
| Lysosome/apoptosis | X | | X | | | | | | | | | | |
| Regulation of actin cytoskeleton | X | X | | X | X | X | X | | | | X | | |
| Cell cycle | X | | X | | X | | X | | | | | | |
| P53 signaling pathway | | | X | X | X | | | | | | | X | |
| Adherens/tight junction | | | | X | | | | | | | | | X |
| Focal adhesion | | X | X | X | X | X | | | | | | | |
| | | | | | | | | | | | | | |
| Insulin signaling pathway | | | X | | | | | | X | | | | |
| Adipocytokine signaling pathway | | | X | | X | | | | | | | | |
| GnRH signaling pathway | | | X | | | | | X | X | | | | |
| Melanogenesis | X | | | | | X | | | | X | | | |
| | | | | | | | | | | | | | |
| Long term potentiation | X | X | | | | | X | | | X | | | |
| Neurotrophin signaling pathway | X | X | X | X | | X | | X | | | | | |
| | X | X | X | X | X | | | X | | X | X | X | |
| | | X | | | | | X | | | | | ||
| | | | | | | | | | | | | | |
| Pathways in cancer | | X | X | X | X | | | X | X | X | X | X | |
| Colorectal cancer | X | X | X | X | | X | | X | | X | X | | |
| Pancreatic cancer | X | | X | X | X | | | | | | | | |
| Bladder cancer | | | X | | | | | | | | | | |
| Prostate cancer | X | X | X | X | X | | | | | | | X | |
| Small cell lung cancer | X | | X | | | | | | | | | X | |
| Non-small cell lung cancer | X | X | X | | X | | | | | | | | |
| Thyroid cancer | | | X | | | | | | | | | | |
| Renal cell carcinoma | X | | | X | X | | | X | | | | | |
| Endometrical cancer | X | | X | | | | | | | | | | |
| Glioma | X | X | X | | X | | | | | | | X | |
| Melanoma | X | | X | | X | | | | | | | X | |
| Type II diabetes mellitus | | X | X | | | | | | | | | | |
| Chronic myeloid leukemia | X | | X | X | X | | | | | | | | |
| Acute myeloid leukemia | X | X | |||||||||||
*Results for miR-21-3p were ignored because only few target genes out of 78 were non-significantly enriched in two pathways (Neurotophin signaling pathway- 3 genes and Ubiquitin mediated pathway- 3 genes). Similarly, only 3 genes each out of 88 target genes for miR-184 were enriched (P > 0.05) in two pathways, Chronic myeloid leukemia and Prostate cancer and were ignored. The target genes for miR-un5, a newly identified miRNA in this study were not determined.